Fecal Occult Blood Testing

Clinics in Laboratory Medicine

Volumn 29, Issue 3, 2009, Pages 523-541

  Sanford, Kimberly W ^a   McPherson, Richard A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Colonoscopy; Colorectal cancer; CT colonography; Fecal DNA test; Fecal immunochemical test; Fecal occult blood testing

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; APC PROTEIN; ASCORBIC ACID; CORTICOSTEROID; GUAIAC; IBUPROFEN; INDOMETACIN; K RAS PROTEIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PROTEIN P53; RESERPINE;

ADENOMATOUS POLYP; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CHROMOSOMAL INSTABILITY; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA EXTRACTION; DRUG MEGADOSE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEMATURIA; HUMAN; IMMUNOCHEMISTRY; LABORATORY DIAGNOSIS; LYMPH NODE METASTASIS; MICROSATELLITE INSTABILITY; OCCULT BLOOD; PRIORITY JOURNAL; REGIONAL METASTASIS; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

COLONOSCOPY; COLORECTAL NEOPLASMS; DNA; EARLY DETECTION OF CANCER; FECES; GUAIAC; HUMANS; IMMUNOASSAY; OCCULT BLOOD;

EID: 70349961769     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.06.008     Document Type: Review

References (68)

1. Cancer facts & figures 2008 (2008), American Cancer Society, Atlanta (GA). http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf Accessed March 28, 2009
2. Rickert R.R., Auerbach O., Garfinkel L., et al. Adenomatous lesions of the large bowel: an autopsy survey. Cancer 43 5 (1979) 1847-1857
3. Inadomi J.M. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence. J Gastroenterol Hepatol 23 Suppl 2 (2008) S198-S204
4. Glenn G.C. Practice parameter on laboratory panel testing for screening and case finding in asymptomatic adults. Arch Pathol Lab Med 120 (1996) 929-943
5. Maciosek M.V., Solberg L.I., Coffield A.B., et al. Colorectal cancer screening: health impact and cost effectiveness. Am J Prev Med 31 1 (2006) 80-89 [PMID: 16777546]
6. Mandel J.S., Bond J.H., Church T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328 19 (1993) 1365-1371
7. Kewenter J., Bjork S., Haglind E., et al. Screening and rescreening for colorectal cancer: a controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 62 (1988) 645-651
8. Klaaborg K., Madsen M.S., Sondergaard O., et al. Participation in mass screening for colorectal cancer with fecal occult blood test. Scand J Gastroenterol 21 (1986) 1180-1184
9. Kronborg O., Fenger C., Sondergaard O., et al. Initial mass screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Funen in Denmark. Scand J Gastroenterol 22 (1987) 677-686
10. Kronborg O., Fenger C., Olsen J., et al. Repeated screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Fenen, Denmark. Scand J Gastroenterol 24 (1989) 599-606
11. Kronborg O., Fenger C., Worm J., et al. Causes of death during the first 5 years of a randomized trial of mass screening for colorectal cancer with fecal occult blood test. Scand J Gastroenterol 27 (1992) 47-52
12. Hardcastle J.D., Farrands P.A., Balfour T.W., et al. Controlled trial of faecal occult blood testing in the detection of colorectal cancer. Lancet 2 (1983) 1-4
13. Hardcastle J.D., Farrands P.A., Balfour T.W., et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer: results for first 107,349 subjects. Lancet 1 (1989) 1160-1164
14. Kronborg O., Fenger C., Olsen J., et al. Randomised study of screening for colorectal cancer with faecal occult blood test. Lancet 348 (1996) 1472-1477
15. Hardcastle J.D., Chamberlain J.O., Robinson M.H.E., et al. Randomised controlled trial of faecal occult blood screening for colorectal cancer. Lancet 348 (1996) 1472-1477
16. Mandel J.S., Church T.R., Ederer R., et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91 5 (1999) 434-437
17. American Academy of Family Physicians. A-E recommendations for clinical preventive services. Available at. http://www.aafp.org/online/en/home/clinical/exam/a-e.html Accessed March 28, 2009
18. American Cancer Society guidelines for the early detection of cancer. Available at:. http://www.cancer.org/docroot/ped/content/ped_2_3x_acs_cancer_detection_guidelines_36.asp Accessed March 28, 2009
19. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124 (2003) 544-560
20. Wilkins T., and Reynolds P.L. Colorectal cancer: a summary of the evidence for screening and prevention. Am Fam Physician 78 12 (2008) 1385-1392
21. Pignone M., Rich M., Teutsch S.M., et al. Screening for colorectal cancer in adults at average risk: a summary of the evidence for US Preventative Services Task Force. Ann Intern Med 137 2 (2002) 132-141
22. Kratochvil J.F., Burriss R.H., Seikel M.K., et al. Isolation and characterization of alpha-guaiaconic acid and the nature of guaiacum blue. Phytochemistry 10 (1971) 2529
23. Beckman Coulter. Hemoccult product instruction Available at. http://www.beckmancoulter.com/literature/ClinDiag/462478-E_HO.pdf Updated September 2003. Accessed March 28, 2009
24. Ouyang D., Chen J., Getzenberg R., et al. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol 100 (2005) 1393-1403
25. Jaffe R.M., Kasten B., Young D.S., et al. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 83 (1975) 824-826
26. Blebea J., and McPherson R.A. False-positive guaiac testing with iodine. Arch Pathol Lab Med 109 (1985) 437-440
27. Allison J.E., Feldman R., and Tekawa I.S. Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. Ann Intern Med 112 5 (1990) 328-333
28. Ahlquist D.A., Wieand H.S., Moertel C.G., et al. Accuracy of fecal occult blood screening for colorectal neoplasia: a prospective study using Hemoccult and HemoQuant tests. JAMA 269 (1993) 1262-1267
29. Sinatra M.A., St. John J.B., and Young G.P. Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Clin Chem 45 1 (1999) 123-126
30. US Preventative Services Task Force. Screening for colorectal cancer recommendation and rationale. Ann Intern Med 137 2 (2002) 96-104
31. Zauber A.G., Knudsen A.B., Rutter C.M., et al. Cost-effectiveness of CT colonography to screen for colorectal cancer (2009), Agency for Healthcare Research and Quality, Rockville (MD). http://www.cms.hhs.gov/determinationprocess/downloads/id58TA.pdf Accessed March 31, 2009
32. Levin B., Hess K., and Johnson C. Screening for colorectal cancer: a comparison of 3 fecal occult blood tests. Arch Intern Med 157 (1997) 970-976
33. Rozen P., Knaani J., and Samuel Z. Comparative screening with a sensitive guaiac and specific immunochemical occult blood test within an endoscopy study. Cancer 89 1 (2000) 46-52
34. St John D.J.B., Young G.P., Alexeyett M.A., et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 104 (1993) 1661-1668
35. Petrelli N., Michalek A.M., Freedman A., et al. Immunochemical versus guaiac occult blood stool tests: results of a community based screening program. Surg Oncol 3 (1994) 27-36
36. Rozen P., Knaani J., and Papo N. Evaluation and comparison of an immunochemical and a guaiac faecal occult blood-screening test for colorectal neoplasia. Eur J Cancer Prev 4 (1995) 475-481
37. Rozen P., Knaani J., and Samuel Z. Performance characteristics and comparison of two immunochemical and two guaiac fecal occult blood screening tests for colorectal neoplasia. Dig Dis Sci 42 10 (1997) 2064-2071
38. Allison J.E., Tekawa I.S., and Ransom L.J. A comparison of fecal occult blood tests for colorectal cancer screening. N Engl J Med 334 3 (1996) 155-159
39. Feinberg E.J., Steinberg W.M., Banks B., et al. How long to abstain from eating red meat before fecal occult blood tests. Ann Intern Med 113 (1990) 403-404
40. Ransohoff D.F., and Lang C.A. Improving the fecal occult blood test. N Engl J Med 334 3 (1996) 189-190
41. US Preventative Services Task Force. Screening for colorectal cancer recommendation statement. Ann Intern Med 149 9 (2008) 627-637
42. Young G.P., John J.B., Winawer S.J., et al. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies. Am J Gastroenterol 97 10 (2002) 2499-2506
43. Rockey D.C., Auslander A., and Greenberg P.D. Detection of upper gastrointestinal blood with fecal occult blood tests. Am J Gastroenterol 94 (1999) 344-350
44. Cole S.R., and Young G.P. Effect of dietary restriction on participation in faecal occult blood test-based screening for colorectal cancer. Med J Aust 175 4 (2001) 195-198
45. Beckman Coulter. Hemoccult ICT immunochemical fecal occult blood test product instructions. Updated June 2005. Available at. http://www.beckmancoulter.com/literature/ClinDiag/1_395069-F.pdf Accessed March 28, 2009
46. Imperiale T. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future [editorial]?. Ann Intern Med 146 4 (2007) 309-311
47. Allison J.E., Sakoda L.C., Levin T.R., et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 99 (2007) 1462-1470
48. Hundt S., Haug U., and Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 150 3 (2009) 162-169
49. CodeMap national for 2008 laboratory fees. Available at. https://www.codemap.com/ivd/userhome.cfm Accessed March 28, 2009
50. Fearon E., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
51. Soreide K., Janssen E.A., Soiland H., et al. Microsatellite instability in colorectal cancer. Br J Surg 93 (2006) 395-406
52. Gryfe R., Kim H., Hsieh E.T.K., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 (2000) 69-77
53. Imperiale T., Ransohoff D.F., Itzkowitz S.H., et al. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med 351 26 (2004) 2704-2714
54. Hoang J.M., Cottu P.H., Thuille B., et al. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 57 (1997) 300-303
55. DNA Direct. DNA stool testing with DNA Direct. Available at. http://www.dnadirect.com Accessed March 28, 2009
56. Ahlquist D.A., Sargent D.J., Loprinzi C.L., et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 149 7 (2008) 441-450
57. Chien C.C., Chen S.H., Liu C.C., et al. Correlation of K-ras codon 12 mutations in human feces and ages of patients with colorectal cancer (CRC). Transl Res 149 (2007) 96-102
58. Woolf S. A smarter strategy? Reflections on fecal DNA screening for colorectal cancer. N Engl J Med 351 26 (2004) 2755-2758
59. Frossard J.L., and Peyer R. Fecal DNA for colorectal cancer screening. N Engl J Med 352 13 (2005) 1384-1385
60. Jimbo M., Myers R.E., Hyslop T., et al. Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med 7 1 (2009) 11-16
61. Myers R.E., Balshem A.M., Wolf T.A., et al. Screening for colorectal neoplasia: physicians' adherence to complete diagnostic evaluation. Am J Public Health 83 11 (1993) 1620-1622
62. Sharma V.K., Vasudeva R., and Howden C.W. Colorectal cancer screening and surveillance practices by primary care physicians: results of a national survey. Am J Gastroenterol 95 6 (2000) 1551-1556
63. Lurie J.D., and Welch H.G. Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst 91 (1999) 1641-1646
64. Shields H.M., Weiner M.S., Henry D.R., et al. Factors that influence the decision to do an adequate evaluation of a patient with a positive stool for occult blood. Am J Gastroenterol 96 1 (2001) 196-203
65. Ko C.W., Dominitz J.A., and Nguyen T.D. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical based tests. Am J Med 115 2 (2003) 111-114
66. Ransohoff D.F., and Lang C.A. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Intern Med 126 (1997) 811-822
67. Rao S.K., Schilling T.F., and Sequist T.D. Challenges in the management of positive fecal occult blood tests. J Gen Intern Med 24 3 (2009) 356-360
68. Whitlock E.P., Lin J.S., Lilies E., et al. Screening for colorectal cancer: an updated systematic review. Evidence synthese no. 65, part 1. AHRQ publication no. 08-05124-EF-1 (2008), Agency for Healthcare Research and Quality, Rockville (MD)